Mitri Zahi, Constantine Tina, O'Regan Ruth
Department of Internal Medicine, Emory University, Atlanta, GA 30322, USA.
Chemother Res Pract. 2012;2012:743193. doi: 10.1155/2012/743193. Epub 2012 Dec 20.
Human epidermal growth factor receptor 2 (HER2) is overexpressed in around 20-30% of breast cancer tumors. It is associated with a more aggressive disease, higher recurrence rate, and increased mortality. Trastuzumab is a HER2 receptor blocker that has become the standard of care for the treatment of HER2 positive breast cancer. The effectiveness of Trastuzumab has been well validated in research as well as in clinical practice. The addition of Trastuzumab to standard of care chemotherapy in clinical trials has been shown to improve outcomes for early stage as well as metastatic HER2 positive breast cancer. The most clinically significant side effect of Trastuzumab is the risk of cardiac myocyte injury, leading to the development of congestive heart failure. The emergence of patterns of resistance to Trastuzumab has led to the discovery of new monoclonal antibodies and other targeted agents aimed at overcoming Trastuzumab resistance and improving survival in patients diagnosed with HER2 positive breast cancers.
人表皮生长因子受体2（HER2）在约20%-30%的乳腺癌肿瘤中过度表达。它与侵袭性更强的疾病、更高的复发率和死亡率增加相关。曲妥珠单抗是一种HER2受体阻滞剂，已成为HER2阳性乳腺癌治疗的标准疗法。曲妥珠单抗的有效性在研究和临床实践中均得到了充分验证。在临床试验中，将曲妥珠单抗添加到标准化疗中已被证明可改善早期和转移性HER2阳性乳腺癌的治疗效果。曲妥珠单抗最具临床意义的副作用是心肌细胞损伤的风险，会导致充血性心力衰竭。对曲妥珠单抗耐药模式的出现促使人们发现了新的单克隆抗体和其他靶向药物，旨在克服曲妥珠单抗耐药性并提高HER2阳性乳腺癌患者的生存率。
